Episurf Medical
-
Recon
First Korean patent approval for Episurf Medical
THU, MAY 28, 2020 12:15 CET Episurf Medical (NASDAQ: EPIS B) has received a Notice of Allowance from the Korean…
Read More » -
Recon
Positive results from follow-up of 30 patients in a Swedish multicentre clinical trial of the Episealer® Knee implant
Episurf Medical (Nasdaq: EPIS B) March 8, 2020 – Today announces that results from a clinical study with follow-up of…
Read More » -
Recon
Episurf Medical reaches milestone of 700 implants
FRI, FEB 21, 2020 09:05 CET Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone…
Read More » -
Recon
Episurf Medical reaches milestone of 600 implants
WED, SEP 18, 2019 Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the…
Read More » -
Recon
Episurf Medical reaches new milestones in its patient population
August 16, 2019 Episurf Medical (Nasdaq: EPIS B) today announces that the company has reached new milestones in its patient…
Read More » -
Extremities
Episurf Medical reaches milestone of 500 implants
Feb 20, 2019 Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of the 500th surgery…
Read More » -
Hospitals
Episurf Medical has received initial feedback from the US FDA on the IDE application for the Episealer® knee implant
MON, JUL 30, 2018 08:30 CET Episurf Medical (NASDAQ: EPIS B) today announces that the company has received initial feedback…
Read More » -
Hospitals
Episurf Medical submits IDE application to the US FDA for the Episealer® knee implant
JUN 28, 2018 Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached an important milestone on its…
Read More » -
Extremities
Episurf Medical enters into distribution agreement in Hong Kong and establishes subsidiary in the US
APR 26, 2018 Episurf Medical (NASDAQ: EPIS B) today announces that the company has entered into a distribution agreement in…
Read More » -
Hospitals
Episurf Medical’s knee products approved for marketing and sale in Spain
TUE, APR 03, 2018 Episurf Medical (NASDAQ: EPIS B) today announces that the Spanish authority AEMPS (Agencia Española de Medicamentos…
Read More » -
Hospitals
New European patent approval for Episurf Medical
MAR 14, 2018 The European patent office EPO has announced its intention to grant another European patent for Episurf Medical…
Read More » -
Extremities
Episurf Medical in the final stages of development of an ankle implant
FEB 14, 2018 With three Episealer® knee implant products currently approved and on the market in Europe, Episurf Medical (NASDAQ:…
Read More » -
Extremities
Episurf Medical reaches milestone of 300 implants
Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of its 300th…
Read More » -
Hospitals
Episurf Medical continues its communication with the US FDA for market acceptance in the U.S.
Press Release – 15.05.2017 In July 2016, Episurf Medical participated in a pre-submission meeting with the FDA in Washington. Following this…
Read More » -
Financial
Episurf Medical – Interim Report, 1 January – 30 September, 2015
Third quarter 2015 for the Group compared to 2014 » Net sales amounted to SEK 150,174 (78,235). » Other operating…
Read More »